FBLG 3.50 FibroBiologics, Inc. Common Stock
| Range: | 1.078-46.0 | Vol Avg: | 427843 | Last Div: | 0 | Changes: | 0.07 |
| Beta: | 0 | Cap: | 0.12B | Currency: | USD | Exchange: | NASDAQ |
| Sector: | Healthcare | IPO: | Thu Feb 01 2024 | Empoloyees: | 10 | ||
| CUSIP: | CIK: | 0001958777 | ISIN: | US31573L1052 | Country: | US | |
| CEO: | Mr. Peter O'Heeron | Website: | https://www.fibrobiologics.com | ||||
FibroBiologics, Inc., a clinical-stage cell therapy company, develops and commercializes fibroblast-based therapies in the United States. It is developing CybroCell, for the treatment of degenerative disc disease; CYMS101 to treat multiple sclerosis; and CYWC628 for wound healing. The company is also on the early-stage research of CYTER915, which is designed to regenerate or reinvigorate production of the thymus and/or spleen; CYPS317, for the treatment of psoriasis; and TCB190 to treat certain cancers. FibroBiologics, Inc. was incorporated in 2021 and is headquartered in Houston, Texas.
Stock Details
About The Monevue
The content provided on this site is for informational purposes only and does not constitute financial, investment, or professional advice. We are not registered investment advisors or financial planners, and we do not provide recommendations or advice on buying, selling, or holding any particular stocks or securities. Any investment decisions should be made based on your own research and consultation with a qualified financial professional. We are not responsible for any financial loss or damages incurred from reliance on the information provided on this site. Please invest responsibly and seek professional advice when needed.
• Powered by StackThrow